CanPrev Nattokinase 100mg 2000 FU - High Potency | 60 Capsules
Visit the CanPrev Store| Brand | CanPrev |
| Serving | 1 capsule daily with food (max. 4 weeks without practitioner guidance) |
| Licensed Natural Health Product | NPN 80092486 |
| Quality Standards | GMP-compliant facility |
| Country | Made in Canada  |
About this item
- 100 MG NSK-SD NATTOKINASE - 2000 FIBRINOLYTIC UNITS: Each vegetable capsule provides 100 mg of high-potency NSK-SD Nattokinase (Glycine max; Bacillus subtilis var. natto), standardized to 2000 fibrinolytic units (FU) - take 1 capsule daily with food, or as directed by a healthcare practitioner.
- HELPS SUPPORT CARDIOVASCULAR SYSTEM HEALTH: The recommended use authorized on this product's Health Canada licence (NPN 80092486): helps support cardiovascular system health.
- A TRADITIONAL FERMENTED-SOY ENZYME: Nattokinase is the fibrinolytic enzyme produced when soybeans are fermented with Bacillus subtilis var. natto to make natto, a traditional Japanese food, here standardized as NSK-SD for consistent daily dosing.
- ONCE-DAILY, HIGH-POTENCY DOSING: One vegetable capsule a day delivers a standardized 2000 FU dose - a 60-day supply per bottle. Consult a healthcare practitioner for use beyond 4 weeks.
- VEGAN CAPSULE, GMO-FREE FORMULA: The vegetable capsule itself is vegan and free of gluten, dairy, wheat, yeast, sugar, artificial colours, flavours and preservatives; the formula does contain soy (see cautions).
- MADE IN CANADA, LICENSED BY HEALTH CANADA: Formulated and made in Canada by CanPrev Natural Health Products Ltd. and licensed under NPN 80092486.
Product Description
Nattokinase - 100 mg NSK-SD Nattokinase, 2000 Fibrinolytic Units per Capsule
CanPrev Nattokinase delivers 100 mg of high-potency NSK-SD Nattokinase (Glycine max; Bacillus subtilis var. natto) in every vegetable capsule, standardized to 2000 fibrinolytic units (FU). Nattokinase is the enzyme naturally produced when soybeans are fermented with Bacillus subtilis var. natto to make natto, a traditional Japanese food. Helps support cardiovascular system health. Once-daily dosing, vegan capsule, and licensed as a Natural Health Product. Licensed Natural Health Product NPN 80092486.
Nattokinase de CanPrev fournit 100 mg de nattokinase NSK-SD de haute puissance (Glycine max; Bacillus subtilis var. natto) dans chaque capsule végétale, normalisée à 2000 unités fibrinolytiques (FU). La nattokinase est l'enzyme naturellement produite lorsque les graines de soja sont fermentées avec Bacillus subtilis var. natto pour fabriquer le natto, un aliment japonais traditionnel. Aide à soutenir la santé du système cardiovasculaire. Dose quotidienne unique, capsule végétalienne, et homologuée comme produit de santé naturel.
Built on NSK-SD - The Original Clinically Studied Nattokinase
100 mg NSK-SD Nattokinase (Glycine max; Bacillus subtilis var. natto) per vegetable capsule, providing 2000 fibrinolytic units (FU)
100 mg NSK-SD Nattokinase per Capsule
Each vegetable capsule delivers a standardized 100 mg dose of NSK-SD Nattokinase, providing 2000 fibrinolytic units (FU) - take 1 capsule daily with food, or as directed by a healthcare practitioner.
A Fermented-Soy Enzyme Format
Nattokinase is the fibrinolytic enzyme produced during the fermentation of natto (soybeans fermented with Bacillus subtilis var. natto) - a traditional Japanese food, now standardized and encapsulated for consistent daily dosing.
Why This Formula
CanPrev Nattokinase is built around one real active - NSK-SD Nattokinase - delivered in a standardized, once-daily vegetable capsule.
Cardiovascular System Support
Helps support cardiovascular system health - this product's Health Canada-authorized use.
100 mg NSK-SD Nattokinase - 2000 FU per Capsule
Each capsule delivers a standardized, high-potency dose of NSK-SD Nattokinase.
A Traditional Fermented-Soy Enzyme
Nattokinase is the fibrinolytic enzyme naturally produced during the fermentation of natto, a traditional Japanese soy food.
Once-Daily, High-Potency Dosing
One vegetable capsule per day delivers a standardized 2000 FU dose - a 60-day supply per bottle.
CanPrev Nattokinase: Supplement Facts
Each capsule contains:
- NSK-SD Nattokinase (Glycine max; Bacillus subtilis var. natto)100 mg (2000 FU)
Non-Medicinal Ingredients: Calcium carbonate, dextrin, food starch, hypromellose, magnesium stearate, maltodextrin, microcrystalline cellulose, soybean oil (soy), soybean powder (soy).
Recommended Use or Purpose: Helps support cardiovascular system health.
Recommended Dose (Adults 19 years and older): Take 1 capsule per day with food, or as directed by a healthcare practitioner. Recommended Duration of Use: Consult a healthcare practitioner for use beyond 4 weeks.
Cautions and Warnings: This product is derived from soy - do not use if you have a soy allergy. Do not use if you are pregnant or breastfeeding, if you are taking health products that affect blood coagulation, or if you have a bleeding disorder. Stop using this product 7 days before any scheduled surgery, or immediately if you have unscheduled surgery or if you suffer from an injury resulting in bruising or bleeding. Consult a healthcare practitioner prior to use if you have a cardiovascular, kidney, or liver disorder, or if you are taking any medications. Do not use if the safety seal is broken. Keep out of reach of children.
Actual product packaging and materials may contain more and different information than what is shown on our website. We recommend that you do not rely solely on the information presented and that you always read labels, warnings, and directions before using or consuming a product. This item is sold and shipped by Amazon.ca.
Chaque capsule contient :
- Nattokinase NSK-SD (Glycine max; Bacillus subtilis var. natto)100 mg (2000 FU)
Ingrédients non médicinaux : Carbonate de calcium, dextrine, amidon alimentaire, hypromellose, stéarate de magnésium, maltodextrine, cellulose microcristalline, huile de soja (soja), poudre de soja (soja).
Usage ou fins recommandés : Aide à soutenir la santé du système cardiovasculaire.
Dose recommandée (adultes de 19 ans et plus) : Prendre 1 capsule par jour avec de la nourriture, ou selon l'avis d'un praticien de soins de santé. Durée d'utilisation recommandée : Consultez un praticien de soins de santé pour une utilisation de plus de 4 semaines.
Mises en garde et avertissements : Ce produit est dérivé du soja - ne pas utiliser en cas d'allergie au soja. Ne pas utiliser si vous êtes enceinte ou allaitez, si vous prenez des produits de santé qui affectent la coagulation sanguine, ou si vous souffrez d'un trouble hémorragique. Cessez d'utiliser ce produit 7 jours avant toute chirurgie programmée, ou immédiatement en cas de chirurgie non planifiée ou de blessure entraînant des ecchymoses ou des saignements. Consultez un praticien de soins de santé avant l'utilisation si vous souffrez d'un trouble cardiovasculaire, rénal ou hépatique, ou si vous prenez des médicaments. Ne pas utiliser si le sceau de sécurité est brisé. Tenir hors de la portée des enfants.
NPN 80092486
Add CanPrev Nattokinase to your daily routine
Get CanPrev Nattokinase on Amazon.ca - fast, protected delivery.
Get it on Amazon.caWhy CanPrev Nattokinase
100 mg of standardized NSK-SD Nattokinase per capsule (2000 FU), in a once-daily vegan capsule made in Canada.
100 mg NSK-SD Nattokinase - 2000 FU per capsule
Each vegetable capsule delivers a standardized, high-potency dose of NSK-SD Nattokinase (Glycine max; Bacillus subtilis var. natto).
A traditional fermented-soy enzyme
Nattokinase is the fibrinolytic enzyme produced when soybeans are fermented with Bacillus subtilis var. natto to make natto, standardized here for consistent dosing.
Simple, once-daily dosing
Take 1 capsule per day with food - a 60-day supply per bottle. Consult a healthcare practitioner for use beyond 4 weeks.
Trusted Canadian brand
CanPrev - formulated and made in Canada, licensed under NPN 80092486.
Inside every capsule
100 mg NSK-SD Nattokinase (Glycine max; Bacillus subtilis var. natto), providing 2000 fibrinolytic units (FU) - take 1 capsule daily with food, or as directed by a healthcare practitioner.
How to use it
Take one capsule daily, with food
Adults (19 years and older): take 1 capsule per day with food, or as directed by a healthcare practitioner.
Limit to 4 weeks without practitioner guidance
Consult a healthcare practitioner for use beyond 4 weeks.
Know when to stop
Stop using this product 7 days before any scheduled surgery, or immediately if you have unscheduled surgery or an injury resulting in bruising or bleeding.
What the research says about Nattokinase
Educational summaries of published research on nattokinase generally; not product-specific claims. CanPrev Nattokinase's own label claim is the use authorized under NPN 80092486: helps support cardiovascular system health.
A single 2000 FU dose of nattokinase measurably enhanced fibrinolysis and anticoagulation in healthy men
In a placebo-controlled cross-over study of 12 healthy young males, a single oral 2,000 FU dose of nattokinase significantly raised D-dimer and fibrin/fibrinogen degradation products, lowered Factor VIII activity, raised antithrombin, and prolonged activated partial thromboplastin time within hours - all changes stayed within the normal range, but the study confirmed nattokinase measurably affects multiple clotting/fibrinolysis pathways at once.
Human RCT8 weeks of nattokinase prolonged bleeding-related clotting times in hypercholesterolemic adults
In 100 subjects with borderline-to-moderate hypercholesterolemia, 8 weeks of nattokinase supplementation significantly increased collagen-epinephrine closure time and activated partial thromboplastin time versus placebo - real, measurable evidence of nattokinase's own anticoagulant-type activity, consistent with why this product's label warns against combining it with other blood thinners.
Human RCTNattokinase reduced thrombus size in a rat tail thrombosis model
Subcutaneous nattokinase given to rats before carrageenan-induced tail thrombosis significantly shortened the length of infarcted (thrombosed) tissue compared to untreated controls, extending nattokinase's known in vitro fibrin-degrading activity to a real in vivo antithrombotic effect.
Animal studyAn 8-week RCT found nattokinase (2,000 FU/day) lowered blood pressure in pre-hypertensive and stage-1-hypertensive adults
In 73 subjects who completed an 8-week, randomized, placebo-controlled trial, nattokinase supplementation reduced systolic blood pressure by 5.55 mmHg and diastolic blood pressure by 2.84 mmHg net of placebo, alongside a reduction in plasma renin activity.
Human RCTA North American RCT found nattokinase (100 mg/day) lowered blood pressure, with sex-specific effects on a clotting-risk marker
In a multicenter, placebo-controlled trial of 74 hypertensive adults, 8 weeks of nattokinase reduced systolic and diastolic blood pressure, with the diastolic reduction reaching high significance in men; a reduction in von Willebrand factor, a cardiovascular risk marker, was seen in women taking nattokinase.
Human RCTA 3-year, 265-person RCT found no significant effect of nattokinase on subclinical atherosclerosis progression or blood pressure
In healthy older adults at low cardiovascular risk, this long-term, double-blinded 'Nattokinase Atherothrombotic Prevention Study' found no significant difference between nattokinase (2,000 FU/day) and placebo in the rate of change of carotid artery intima-media thickness, carotid arterial stiffness, blood pressure, or any laboratory measure - an honest null result in a low-risk population, included here for balance alongside the positive hypertension trials above.
Human RCTA 1,062-participant clinical study found a higher nattokinase dose improved lipid profile and carotid-artery measures over 12 months
Comparing nattokinase at 10,800 FU/day versus a lower 3,600 FU/day dose over a year, the higher dose was associated with an improved lipid profile and reductions in carotid artery intima-media thickness and plaque size, while the lower dose showed no such benefit; no notable adverse effects were reported at the higher dose. (Note: a 2022 corrigendum was later issued for this article; only the qualitative, dose-dependent finding is summarized here.)
Clinical studyA 26-week RCT found nattokinase reduced carotid plaque size more than simvastatin, though simvastatin cut cholesterol more
In 76 patients randomized to nattokinase (6,000 FU/day) or simvastatin (20 mg/day), nattokinase produced a significantly larger reduction in carotid artery plaque size (36.6% vs 11.5%) and raised HDL-cholesterol, while simvastatin produced a greater reduction in total cholesterol, LDL-C and triglycerides - suggesting nattokinase's plaque-reducing effect may work through a pathway independent of its lipid effects.
Human RCTA 4-month RCT of a nattokinase-red yeast rice combination improved cholesterol markers but not carotid thickness
In 113 adults with dyslipidemia, a combination supplement containing nattokinase and Monascus (red yeast rice) significantly reduced total cholesterol, LDL-C and non-HDL-C versus placebo over 120 days, with no treatment-related adverse events, though carotid intima-media thickness did not significantly change - a partial, honest result for this combination formula (not nattokinase alone).
Human RCTNattokinase reduced inflammation and oxidative stress in a mouse model of endotoxin-triggered clotting
In mice, nattokinase reduced ear swelling and protected against LPS-induced acute kidney injury by suppressing inflammatory signaling (TLR4/NOX2/NF-kB) in macrophages, and lowered PAI-1 levels that otherwise drive fibrin deposition and glomerular thrombus formation - extending nattokinase's antithrombotic profile beyond direct fibrin breakdown to anti-inflammatory pathways.
Animal/in vitro studyNattokinase combined with heparin produced a synergistic anticoagulant effect in lab and animal testing
Nattokinase-heparin combinations produced a synergistic increase in clotting time in vitro and in vivo, and nattokinase was shown for the first time to degrade all three chains of fibrinogen directly - real mechanistic evidence for why combining nattokinase with an anticoagulant drug like heparin measurably changes bleeding-risk parameters, supporting this product's own caution against combining it with blood-coagulation-affecting medication.
Animal/in vitro studyNattokinase reduced vascular inflammation in endothelial cells and a mouse model via autophagy-related gene pathways
In endothelial cells and mice, nattokinase upregulated SRF and THBS1 gene expression, increased protective autophagy, and inhibited NLRP3 inflammasome formation and necroptosis - a proposed mechanism by which nattokinase may help reduce vascular inflammation associated with atherosclerosis.
Animal/in vitro studyA pharmacology review outlined nattokinase's fibrinolytic, antihypertensive, anti-atherosclerotic and lipid-lowering effects
This review of nattokinase's cardiovascular pharmacology concluded it possesses several favourable cardiovascular effects supported by available evidence, while also flagging outstanding questions around its pharmacokinetics as an area needing further research.
ReviewA 2026 review proposed a framework for using nattokinase to manage thrombophilia (clot-prone states)
This review described nattokinase's antithrombotic effects as working through multiple mechanisms - direct fibrin degradation, inhibition of platelet aggregation, and antioxidant/anti-inflammatory action - while noting real translational bottlenecks including pH/thermal stability and a current lack of standardization and large-scale clinical evidence.
ReviewA bibliometric review mapped eight decades of global research on fibrinolytic enzymes including nattokinase
Analyzing publication trends across 35 countries, this review found South Korea leads institutional output on fibrinolytic enzymes like nattokinase, identified immunogenicity, bleeding risk and short half-life as recurring translational challenges, and highlighted Thrombosis Research and the Journal of Microbiology and Biotechnology as prominent publishing venues in the field.
ReviewA real-world study of 153 vascular-surgery patients found nattokinase safe when carefully monitored alongside anticoagulant drugs
Patients with deep vein thrombosis, phlebitis or venous insufficiency were given nattokinase (100 mg/day) together with prescription anticoagulants (fondaparinux or enoxaparin) under close INR monitoring and dose adjustment; symptoms improved with no adverse drug reactions or interactions recorded - the authors stressed that careful clinical monitoring, not unsupervised self-combination, is what made this safe.
Clinical studyA published case report documented a cerebellar hemorrhage after combining nattokinase with aspirin
A patient already taking aspirin for stroke prevention, who also had pre-existing cerebral microbleeds, suffered an acute cerebellar hemorrhage after taking 400 mg of nattokinase daily for 7 consecutive days - a real documented adverse event illustrating why this product's own label warns against combining it with other blood-thinning medication, especially in anyone with a bleeding-prone condition.
Case reportA 2025 review flagged nattokinase among several cardiovascular nutraceuticals that carry a real bleeding-risk profile
Reviewing anti-atherosclerotic supplements including omega-3s, berberine, garlic and nattokinase, the authors noted these agents' antithrombotic and vascular benefits can come with meaningful bleeding risk or drug interactions, and recommended individualized use with further large-scale trials to establish safety - directly relevant to this product's own caution against use alongside blood-coagulation-affecting medication.
ReviewA 6-month RCT found nattokinase did not improve overall cognition in carotid/intracranial stenosis patients, but showed a selective visuospatial benefit
In 120 patients with asymptomatic intracranial or carotid artery stenosis randomized to nattokinase (8,000 FU/day) or placebo for 6 months, overall cognitive scores (MoCA) did not differ significantly between groups - an honest null primary result - though an exploratory analysis found a reduced risk of visuospatial-function decline in the nattokinase group.
Human RCTA nattokinase-based supplement, used alongside standard care, supported recovery after ischemic stroke
In 61 patients in the subacute stage of ischemic stroke, adding a nattokinase-based product (Nattospes) to standard rehabilitation care was associated with improved physical activity scores, blood pressure control and lipid panels versus standard care alone, with no adverse effects reported over 60 days.
Human RCTOral nattokinase reduced brain infarct size in a rat stroke model through an antioxidant pathway
In rats given nattokinase daily before induced cerebral artery occlusion, nattokinase dose-dependently reduced brain infarct volume and prolonged clotting time, with the effect linked to activation of the Nrf2 antioxidant pathway - early mechanistic evidence for nattokinase as a potential oral adjunct in ischemic stroke management.
Animal studyA 6-month RCT found nattokinase alone did not improve blood lipids, but combining it with red yeast rice did
In 47 adults with hyperlipidemia, a nattokinase-only formula (50 mg/capsule) showed no significant effect on blood lipids after 6 months, while a combination formula of nattokinase with red yeast rice extract significantly reduced triglycerides, total cholesterol and LDL-C and raised HDL-C starting from month one - an honest result showing nattokinase alone was not sufficient in this trial.
Human RCTA 90-day RCT found nattokinase plus red yeast rice improved lipid and clotting markers in coronary artery disease patients
In 178 patients with stable coronary artery disease already on multiple heart medications, nattokinase combined with red yeast rice produced the largest reductions in triglycerides, total cholesterol and diastolic blood pressure, and the largest increase in HDL-cholesterol, versus either supplement alone or placebo, with no adverse effects reported from the combination.
Human RCTAn EPA-nattokinase nanoemulsion improved stability and thrombolytic activity in preclinical testing
Combining nattokinase with EPA (an omega-3 fatty acid) in a nanoemulsion delivery system improved environmental stability and produced a synergistic anti-thrombotic effect against carrageenan-induced thrombosis in preclinical testing, illustrating an active area of research into delivery formats that could improve nattokinase's real-world stability and bioavailability.
Laboratory studyFrequently asked questions
How do I take CanPrev Nattokinase?
Adults (19 years and older): take 1 capsule per day with food, or as directed by a healthcare practitioner. Consult a healthcare practitioner for use beyond 4 weeks.
What's in each capsule?
Each capsule contains 100 mg of NSK-SD Nattokinase (Glycine max; Bacillus subtilis var. natto), providing 2000 fibrinolytic units (FU). Non-medicinal ingredients are calcium carbonate, dextrin, food starch, hypromellose, magnesium stearate, maltodextrin, microcrystalline cellulose, soybean oil (soy) and soybean powder (soy).
What is NSK-SD Nattokinase?
NSK-SD is a standardized, high-potency form of nattokinase (Japan Bio Science Laboratory) - the fibrinolytic enzyme produced when soybeans are fermented with Bacillus subtilis var. natto to make natto, a traditional Japanese food.
What is the licensed use of this product?
This product's Health Canada licence (NPN 80092486) authorizes it to help support cardiovascular system health.
Can I take this if I'm on blood thinners or have a bleeding disorder?
No. Do not use this product if you are taking health products that affect blood coagulation (including anticoagulant or antiplatelet medication) or if you have a bleeding disorder. Nattokinase has its own fibrinolytic and anticoagulant activity, and combining it with blood-thinning medication can increase bleeding risk. Consult a healthcare practitioner before use if you are taking any medications.
Do I need to stop taking this before surgery?
Yes. Stop using this product 7 days before any scheduled surgery, or immediately if you have unscheduled surgery or if you suffer an injury resulting in bruising or bleeding.
Can I take this if I'm pregnant or breastfeeding?
No. Do not use if you are pregnant or breastfeeding.
Is this suitable if I have a soy allergy?
No. This product is derived from soy - do not use if you have a soy allergy.
Is it vegan and allergen-friendly otherwise?
The vegetable capsule itself is vegan, and the formula is free of gluten, dairy, wheat, yeast, sugar and artificial colours, flavours or preservatives - it does contain soy (see the soy-allergy caution above).
Is CanPrev Nattokinase made in Canada?
Yes. It is formulated and made in Canada by CanPrev Natural Health Products Ltd. and licensed by Health Canada under NPN 80092486.
Add CanPrev Nattokinase to your daily routine
Get CanPrev Nattokinase on Amazon.ca - fast, protected delivery.
Get it on Amazon.caNatural Health Product NPN 80092486. Helps support cardiovascular system health. Research summaries on this page concern nattokinase generally and are educational - they are not additional product-specific claims beyond this product's Health Canada-authorized use. Read and follow the label. This product is derived from soy - do not use if you have a soy allergy. Do not use if you are pregnant or breastfeeding, if you are taking health products that affect blood coagulation, or if you have a bleeding disorder. Stop using this product 7 days before any scheduled surgery, or immediately if you have unscheduled surgery or if you suffer from an injury resulting in bruising or bleeding. Consult a healthcare practitioner before use if you have a cardiovascular, kidney, or liver disorder, or if you are taking any medications, and for use beyond 4 weeks. Results may vary.
Important information
Safety Information
Cautions and Warnings: This product is derived from soy - do not use if you have a soy allergy. Do not use if you are pregnant or breastfeeding, if you are taking health products that affect blood coagulation, or if you have a bleeding disorder. Stop using this product 7 days before any scheduled surgery, or immediately if you have unscheduled surgery or if you suffer from an injury resulting in bruising or bleeding. Consult a healthcare practitioner prior to use if you have a cardiovascular, kidney, or liver disorder, or if you are taking any medications. Do not use if the safety seal is broken. Keep out of reach of children.
Indications
Recommended Use or Purpose: Helps support cardiovascular system health.
Ingredients
Medicinal Ingredients (per capsule): NSK-SD Nattokinase (Glycine max; Bacillus subtilis var. natto), 100 mg, providing 2000 fibrinolytic units (FU). Non-medicinal Ingredients: Calcium carbonate, dextrin, food starch, hypromellose, magnesium stearate, maltodextrin, microcrystalline cellulose, soybean oil (soy), soybean powder (soy).
Directions
Recommended Dose (Adults 19 years and older): Take 1 capsule per day with food, or as directed by a healthcare practitioner. Recommended Duration of Use: Consult a healthcare practitioner for use beyond 4 weeks.
Legal Disclaimer
Actual product packaging and materials may contain more and different information than what is shown on our website. We recommend that you do not rely solely on the information presented and that you always read labels, warnings, and directions before using or consuming a product. This item is sold and shipped by Amazon.ca.